Seizing the moment: The U.S. Congress's opportunity to revolutionize cancer screening
This year, the U.S. Congress has a unique opportunity to strike a significant — and swift — blow against cancer.
Last Congress, U.S. Sen. Mike Crapo, R-Idaho, led efforts to advance legislation establishing access to multi-cancer early detection (MCED) tests. The Medicare Multi-Cancer Early Detection Screening Coverage Act would make a meaningful difference in how cancer is screened for and detected. The bill has sweeping support — both inside and outside of Congress — and, after enormous progress last session, it is ready for quick enactment this year.
Sen. Crapo's bill would remove regulatory red tape and create a pathway for MCED tests to be available to those who need them most.
For the nearly 1 million Medicare beneficiaries who will be diagnosed with cancer this year, access to these life-changing tests could mean catching their illnesses earlier — when it can be more easily treated. Catching cancer earlier not only improves a patient's chance of successful treatment, it also reduces the costly burden of cancer care, often helping patients and families avert expensive late-stage treatments and, more importantly, preserving hope and health.
Today's screening methods are the best tool we have against cancer, yet only five cancers — breast, cervical, colorectal, lung, and prostate — currently have broadly accessible methods. Because of this, more than 70% of U.S. cancer deaths are caused by cancers without approved early detection methods. Many patients with these cancers aren't diagnosed until their cancer is at a more advanced stage, requiring more invasive treatment – and all the physical, emotional, and financial strain that comes with it.
Here in Idaho, residents experience higher rates of some cancer types compared to the national average. If broad access to MCED tests becomes available, more Idahoans could have a better chance at beating the disease before it advances to more dangerous stages.
MCED blood tests can detect the presence and location of dozens of cancer types with a high degree of accuracy. Because the test requires only a simple blood draw, it is easy to administer in rural areas and in smaller clinics that may not have specialized equipment. This accessibility is particularly crucial in states like Idaho, where large portions of the population live far from major health care centers.
Early detection dramatically increases the likelihood of successful treatment, a fact underscored by the support for this legislation from medical associations across the state. Endorsers include the Idaho Academy of Family Physicians, Idaho Center for Nursing, Idaho Medical Association, Idaho Society of Clinical Oncology, American Nurses Association of Idaho, Nurse Leaders of Idaho, and the Nurse Practitioners of Idaho – all of which recognize the potential of MCED tests to improve patient outcomes.
The Medicare Multi-Cancer Early Detection Screening Coverage Act would allow Medicare to cover MCED tests once they are approved by the FDA. This coverage is critical because most cancer diagnoses occur in people aged 65 and older. Enabling Medicare coverage would provide seniors with access to the latest in life-changing cancer screening technology — in the same way that it can be available in the private sector. This could level the playing field for older Americans, providing them with more options to catch cancer early and pursue treatment in its most manageable stages.
In the last Congress, nearly 400 lawmakers and over 500 advocacy organizations supported Sen. Crapo's bill. It has also already been deeply vetted by Congressional committees. With such a strong foundation of support — and an urgent need for better cancer detection — this legislation is now ready for swift passage.
Congress has the chance to secure an early and meaningful victory against cancer by passing this legislation now – potentially saving countless lives and sparing families the devastation of late-stage cancer diagnoses.
Thanks to Sen. Crapo's immense leadership, the Medicare Multi-Cancer Early Detection Screening Coverage Act is teed up for quick enactment this year. Idaho's cancer advocacy community is hopeful that Congress will now seize the moment without delay.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
2 hours ago
- Bloomberg
How the Moms and Dads of Patients Won Sarepta's Drug a Reprieve
By and Robert Langreth Save The parents leaped into action as soon as health officials asked Sarepta Therapeutics Inc. to stop selling an expensive gene therapy used to treat a rare muscle disease that affects boys and young men. Some traveled to Washington to meet with members of Congress. Others reached out to White House contacts. Still others wrote letters to the Food and Drug Administration directly. They demanded the FDA restore access to the drug Elevidys for Duchenne muscular dystrophy — even though a big trial failed to prove it slowed the disease's progression. In fact, for some, the treatment appeared to be deadly.
Yahoo
7 hours ago
- Yahoo
TD Cowen Reiterates Buy Rating on Molina Healthcare (MOH) Stock
Molina Healthcare, Inc. (NYSE:MOH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 28, Ryan Langston, an analyst from TD Cowen, reiterated a 'Buy' rating on the company's stock, and the associated price target was lowered to $203.00. The analyst noted that Molina Healthcare, Inc. (NYSE:MOH) continues to effectively manage the medical costs in the challenging environment, mainly in Medicaid, where it is witnessing pressures in behavioral, pharmacy, and inpatient/outpatient care. A doctor in scrubs shaking hands with a patient, representing the healthcare services provided to individuals and families. Molina Healthcare, Inc. (NYSE:MOH) continues to actively work with state partners in order to restore Medicaid rates to appropriate levels. It has considered increased cost trends in the Medicare and Marketplace bids for 2026. Despite challenges, Molina Healthcare, Inc. (NYSE:MOH)'s strategic efforts and adjustments in rate filings reflect growth potential, justifying the analyst's rating. For FY 2025, the Premium revenue is expected to be ~$42 billion, reflecting an increase of ~9% from FY 2024. Molina Healthcare, Inc. (NYSE:MOH) expects its FY 2025 GAAP earnings to be no less than $16.90 per diluted share. Oakmark Funds, advised by Harris Associates, released its Q2 2025 investor letter. Here is what the fund said: 'Molina Healthcare, Inc. (NYSE:MOH) is a leading managed care company. The company is the fourth largest player in managed Medicaid and has consistently delivered industry-leading margins historically. In our view, this is thanks to Molina Healthcare's exceptional management team and culture of operational excellence. Moreover, we think Molina Healthcare has a long runway for growth given its small scale relative to peers and untapped opportunities in their Medicare and Marketplace business segments. Recently, the Medicaid industry has come under substantial pressure due to a challenging redetermination cycle and additional headwinds from legislation under the current administration. This provided the opportunity to, in our view, purchase shares in a best-in-class managed care company at depressed valuation on trough earnings.' While we acknowledge the potential of MOH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock
UnitedHealth Group Incorporated (NYSE:UNH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On August 7, Mizuho analyst Ann Hynes kept her 'Buy' rating, expecting long-term value despite reducing the price objective to $300. The analyst noted that the company has reinstated its 2025 earnings guidance. The analyst believes that pricing pressure and increased medical cost trends will continue into 2026. Furthermore, the analyst also highlighted the underperformance in Optum Health's value-based care and Optum Insight segments. Despite these factors, Hynes opines that UnitedHealth Group Incorporated (NYSE:UNH)'s scale, market position, and diversified business are the key strengths, and believes that the stock's valuation is attractive. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH)'s Q2 2025 revenues increased $12.8 billion YoY to $111.6 billion. This was aided by growth in UnitedHealthcare and Optum. Notably, the Q2 2025 consolidated medical care ratio stood at 89.4%, reflecting an increase of 430 bps YoY. This was mainly because of medical cost trends, which significantly surpassed pricing trends, such as both unit costs and the intensity of services delivered, and the ongoing impacts of Medicare funding reductions. Hotchkis & Wiley, an investment management company, released its Q2 2025 investor letter and mentioned UnitedHealth Group Incorporated (NYSE:UNH). Here is what the fund said: 'UnitedHealth Group Incorporated (NYSE:UNH) is a large US health insurer. Until very recently, UNH traded at a material premium to its peers, reflecting its status as a premium growth stock with momentum. We did not own the stock. However, recent negative headlines, combined with the first earnings miss in 10 years, resulted in a >50% selloff in the company's shares. This decline contributed positively to the strategy's relative performance vs. the index, where UNH was a meaningful weight. We purchased UNH shares after the selloff at what we believe is a compelling valuation.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.